Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials

Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has bee...

Source: Lipids in Health and Disease - September 26, 2023 Category: Lipidology Authors: Asger Wretlind, Viktor Rotbain Curovic, Andressa de Zawadzki, Tommi Suvitaival, Jin Xu, Emilie Hein Zobel, Bernt Johan von Scholten, Rasmus Sejersten Ripa, Andreas Kjaer, Tine Willum Hansen, Tina Vilsb øll, Henrik Vestergaard, Peter Rossing and Cristina Tags: Research Source Type: research